Abstract:Wei-Ying Diao, 1, &ast Cheng-Long Ding, 1, &ast Bo-Yang Yuan, 2 Zan Li, 3 Na Sun, 4 Jia-Bin Huang 5 1 Department of Pathology, The First Affiliated Hospital of Jiamusi University, Jimusi City, Heilongjiang Province, 154002, People's Republic of China; 2 Department of Acupuncture and Moxibustion, The First Affiliated Hospital of Jiamusi University, Jimusi City, Heilongjiang Province, 154002, People's Republic of China; 3 Department of Analytical Chemistry Teaching and Research, Jiamusi University, Jiamusi City, Heilongjiang Province, 154002, People's Republic of China; 4 Graduate Department, Jiamusi University, Jiamusi, Heilongjiang Province, 154002, People's Republic of China; 5 Department of Geratology, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang Province, 154002, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jia-Bin Huang Email Introduction: We aim to investigate the relationship between HER2 gene phenotype and clinical characteristics, distribution and prognosis of non-small cell lung cancer (NSCLC) patients. Methods: A total of 249 NSCLC patients admitted to the oncology department of our hospital from January 2015 to January 2018 were retrospectively analyzed. The clinicopathological information, CT signs, clinical efficacy and long-term prognosis were collected and compared. Results: A total of 249 NSCLC patients underwent HER2 gene testing, 21 of them (8.43%) complied with HER2 alterations [HER2 (+)], and there were significant differences in tumor stages among patients with different HER2 phenotypes ( P 0.05). The disease control rate of HER2 (+) patients was significantly lower than that of HER2 (-) patients, and the 12-month progression-free survival rate and survival rate of HER2 (+) patients were significantly higher than those of HER2 (-) patients ( P < 0.05). There was no significant difference in the incidence of ADR among HER2 patients with different phenotypes, but the incidence of ADR (adverse drug reaction) in HER2 (+) patients with Grade 3 or 4 was significantly higher than that in the control group ( P < 0.05). Discussion: The incidence of HER2 gene mutations in NSCLC patients is relatively low, but it is far commoner in patients with stage IIIB∼IV, among which exon 20 mutations are the most prevalent. In CT signs, the lesion lobulated sign/spiculated sign, necrosis signs, and pleural depression signs are related to HER2 gene mutations. In addition, HER2 gene mutations play a crucial role in the clinical prognosis and treatment safety of patients. Keywords: non-small cell lung cancer, HER2 genotype, CT signs, afatinib As one of the most prevalent malignant tumors worldwide, lung cancer has become the top cause of cancer-related death in the urban population of China. Non-small cell lung cancer (NSCLC) includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma, in which cancer cells grow and divide more slowly, and spread and metastasize are less drastic. 1,2 NSCLC accounts for about 80% of overall lung cancers, and approximately 75% of patients have progressed in the advanced stage when diagnosed, with somber 5-year survival rate. 3 At present, the treatment of NSCLC mainly includes surgery, radiotherapy, chemotherapy, immunotherapy, etc. A large number of studies have shown that the occurrence and development of lung cancer are consequent to the unbalanced regulation of multiple gene expression, which is closely related to the stability of genes in organisms. 4,5 Human Epithelial Factor Receptor-2 (HER2) is a member of the epithelial factor receptor family. Studies demonstrated that HER2 overexpression is an enhancer of EGFR signaling, and it plays a role in signal transduction in cancer development and progress when HER2 is dysfunctional. 6 Afatinib and trezizumab have been recommended as targeted therapies for patients with HER2 mutation -Abstract Truncated-

HER2 Transmembrane Domain Mutation: Comprehensive Characteristics and Real-World Evidence of Treatment Response in Chinese Lung Adenocarcinoma.

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

Clinical Management of Lung Adenocarcinoma Patients with HER2 V659E Mutation.

HER-2 Mutations in Chinese Lung Adenocarcinoma Patients with Negative EGFR Mutations.

Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer

Comprehensive Investigation of Mutational Features of Various Lung Adenocarcinoma Histological Subtypes among Chinese Patients.

Abstract 620: Associations of Genomic Alteration, Tumor Mutational Burden with PD-L1 Expression and Response to Immune Checkpoint Inhibitors in Chinese Lung Patients

HER2-Activating Missense Mutations in Advanced Non-Small Cell Lung Cancer: Rare but Targetable Spot Should Not Be Neglected

The Efficacy of Ado-Trastuzumab Emtansine in Patients with HER-2-aberrant Non-Small Cell Lung Cancer.

Characteristics of the immunogenicity and tumor immune microenvironment in HER2-amplified lung adenocarcinoma

Characteristics of the immunogenicity and tumor immune microenvironment in <i>HER2</i>-amplified lung adenocarcinoma

P1.02-046 Mutational Subtypes and Prognosis of Non-Small-Cell Lung Cancer Harboring HER2 Mutations

MA08.09 Clinical Management of Lung Adenocarcinoma Patients with HER2 V659E Mutation

Comprehensive Profiling of MDM2/TP53 Genomic Aberration in Chinese Patients with Diverse Malignancies.

A Narrative Review of Advances in Treatment and Survival Prognosis of HER2-positive Malignant Lung Cancers

Mutation Variants and Co-Mutations As Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma.

Genetic Alteration Profiling of Chinese Lung Adenocarcinoma and Its Effect on Targeted Therapy Efficacy

Impact of HER2 Mutation Status on Personalized Molecular Targeted Therapy in Advanced Breast Cancers

Lung adenocarcinoma with<i> ERBB2</i> exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy

Clinical Characteristics and Treatment Outcomes of HER2 Mutation and HER2 Fusion in 22 Patients with Advanced Breast Cancer.

The Efficacy of Ado-trastuzumab Emtansine in HER-2 Aberrant Non-Small Cell Lung Cancer